



# BANDARAM PHARMA PACKTECH LIMITED

CIN: L93090KA1993PLC159827

To,

Date: 14.02.2025

**BSE Limited**

P.J.Towers, Dalal Street  
Mumbai - 400001

Dear Sir/Madam,

**Sub: Outcome of Board Meeting held on 14.02.2025.**

**Unit: Bandaram Pharma Packtech Limited (BSE Scrip code: 524602)**

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Bandaram Pharma Packtech Limited held on Friday, 14.02.2025 at 01:00 p.m. at the Registered Office of the Company situated at 601, 5<sup>th</sup> Floor, Oxford Towers, Opp to Leela Palace Hotel, Old Airport Road, Kodihalli Bangalore- 560008, Karnataka, interalia, the following were considered and approved:

1. Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31.12.2024. **(Enclosed)**
2. Limited Review Report (standalone and consolidated) for the quarter and nine months ended 31.12.2024. **(Enclosed)**
3. Appointment of Mr. NSK Aakarsh Raj (DIN: 09530950) as an Additional Director (Executive category) of the Company w.e.f. 14.02.2025, subject to the approval of the shareholders in the ensuing extra ordinary general meeting.

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore-560008  
Ph No.: 9900002025, E-mail: info.bandaram@gmail.com



# BANDARAM PHARMA PACKTECH LIMITED

CIN: L93090KA1993PLC159827

4. Appointment of M/s. Manoj Parakh and Associates as Secretarial Auditors of the Company for the FY 2024 – 25.
5. Prior Approval of the shareholders to be taken for the Material Related Party Transactions to be entered with M/s. VSR Paper and Packaging Limited, Subsidiary of the Company.
6. Extra Ordinary General Meeting of the shareholders will be held on Friday, 14.03.2025 through video conferencing or other audio visual means for the items mentioned at sl. nos. 3 and 5.

Disclosures as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/ 120 dated 11<sup>th</sup> July, 2023] **Enclosed as Annexure A and B.**

The meeting concluded at 04:50 p.m.

Thanking you.

Yours sincerely,

**For Bandaram Pharma Packtech Limited**

B  
Deepak  
Reddy

Digitally  
signed by B  
Deepak  
Reddy

**B. Deepak Reddy**

**Chairman and Managing Director**

**DIN: 07074102**



Encl: as above

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to Leela Palace  
Hotel, Old Airport Road, Kodihalli, Bangalore-560008  
Ph No.: 9900002025, E-mail: info.bandaram@gmail.com



# BANDARAM PHARMA PACKTECH LIMITED

CIN: L93090KA1993PLC159827

## Annexure A

**Disclosure as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/ 120 dated 11th July, 2023]**

<b>Particulars</b>	<b>Mr. NSK Aakarsh Raj (DIN:09530950)</b>
Reason for change viz. Resignation/ appointment	Appointment as an Additional Director (Executive category) of the Company.
Date of Appointment / Cessation	14/02/2025
Terms of appointment	Appointed w.e.f. 14.02.2025 up to ensuing General Meeting or 3 months from the date of appointment whichever is earlier.
Brief profile (in case of appointment)	Mr. NSK Aakarsh Raj has done graduation in B.Tech (Production and Industrial Engineering) from Vellore Institute of Technology and IGCSE from Shree Swaminarayan Gurukul International School.  His expertise is in Strategic Branding and Fund Management etc. His core competencies is in Business Development, Strategic Planning, Operational Efficiency and Financial Analysis. He is also Founder and Director of Alphabulls Venture Private Limited.
Disclosure of relationships between directors (in case of appointment of a director)	Nil
Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any	NA
No. of shares held in the Company	Nil

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore-560008  
Ph No.: 9900002025, E-mail: info.bandaram@gmail.com



# BANDARAM PHARMA PACKTECH LIMITED

CIN: L93090KA1993PLC159827

Information as required under circular No. LIST/COMP/14/2018-19 dated 20.06.2018	Mr. NSK Aakarsh Raj is not debarred from holding office of a director by virtue of any SEBI Order or any other such authority.
--	--

## Annexure B

**Disclosure as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/ 120 dated 11th July, 2023]**

<b>Particulars</b>	<b>M/s. Manoj Parakh and Associates</b>
Reason for change viz. Resignation/ appointment	Appointment of M/s. Manoj Parakh and Associates as Secretarial Auditors of the Company for the FY 2024 - 25
Date of Appointment and Terms of appointment	Appointed on 14.02.2025 For the FY 2024 - 25
Brief profile	Manoj Parakh & Associates, is a Practicing Company Secretaries firm based at Visakhatapatnam providing secretarial, filings and incorporations, foreign advisory services. The firm has existence of more than a decade in the above said services.
Disclosure of relationships between directors (in case of appointment of a director)	NA

Regd. & Corporate Office: Oxford Towers, Unit No. 601, 5th floor, Opp. to Leela Palace Hotel, Old Airport Road, Kodihalli, Bangalore-560008  
Ph No.: 9900002025, E-mail: info.bandaram@gmail.com

BANDARAM PHARMA PACKTECH LIMITED (Formerly Known as Shiva Medicare Limited)													
CIN: L23090KA1993PLC159627													
Regd Office: 601,5th Floor, Oxford Towers, Opp. to Lada Palace Hotel, Old Airport Road, Kodihalli, Bangalore - 560008.													
Statement of Unaudited Results for the Quarter Ended and Nine Months Ended 31-12-2024													
(Rs. in Lakhs)													
S.No.	Particulars	STANDALONE					CONSOLIDATED						
		For the Quarter ended			Nine Months ended		For the Quarter ended			Nine Months ended		Previous Year ended	
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Audited)	31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)	
I	Revenue from Operations	263.15	316.61	570.43	851.91	1,334.35	1,483.91	999.80	710.83	736.25	2,847.26	2,048.56	3,407.89
II	Other Income	-	-	-	-	-	2.68	-	-	-	-	-	3.32
III	<b>Total Income (I+II)</b>	<b>263.15</b>	<b>316.61</b>	<b>570.43</b>	<b>851.91</b>	<b>1,334.35</b>	<b>1,486.59</b>	<b>999.80</b>	<b>710.83</b>	<b>736.25</b>	<b>2,847.26</b>	<b>2,048.56</b>	<b>3,411.21</b>
IV	Expenses												
	(a) Cost of Materials consumed	237.82	226.03	603.70	732.97	1,284.27	1,288.73	812.13	517.08	979.48	2,657.80	2,300.05	3,008.90
	(b) Purchase of stock-in-trade	-	-	-	-	-	-	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-66.62	-	-66.62	-	26.10	-24.62	-398.81	-347.47	-717.53	(283.54)
	(d) Employee benefits expenses	16.44	30.68	21.61	64.49	67.16	114.06	59.53	69.23	69.95	187.31	143.36	232.60
	(e) Finance Cost	-	-	-	-	-	0.01	23.94	26.00	17.18	71.20	61.68	83.44
	(f) Depreciation and amortisation expenses	0.18	0.28	0.38	0.94	1.15	1.54	15.18	15.36	18.19	45.84	54.03	72.91
	(g) Other expenses	4.02	26.54	4.52	41.00	30.49	65.13	36.37	40.59	38.38	121.31	113.88	138.24
	<b>Total Expenses</b>	<b>298.46</b>	<b>283.53</b>	<b>563.59</b>	<b>839.00</b>	<b>1,316.45</b>	<b>1,469.47</b>	<b>972.25</b>	<b>643.64</b>	<b>724.37</b>	<b>2,785.69</b>	<b>1,955.17</b>	<b>3,292.55</b>
V	<b>Profit / (Loss) before and exceptional items and Tax ( III-IV)</b>	<b>4.69</b>	<b>33.08</b>	<b>6.84</b>	<b>12.91</b>	<b>17.90</b>	<b>17.12</b>	<b>26.55</b>	<b>67.19</b>	<b>11.88</b>	<b>111.57</b>	<b>93.39</b>	<b>118.66</b>
VI	Exceptional Items	-	-	-	-	-	-	-	-	-	-	-	-
VII	<b>Profit / (Loss) from before tax (V-VI)</b>	<b>4.69</b>	<b>33.08</b>	<b>6.84</b>	<b>12.91</b>	<b>17.90</b>	<b>17.12</b>	<b>26.55</b>	<b>67.19</b>	<b>11.88</b>	<b>111.57</b>	<b>93.39</b>	<b>118.66</b>
VIII	Tax expense												
	Current Tax	3.23	-	-	3.23	-	4.28	27.89	-	-	27.89	-	21.88
	Deferred Tax	(0.01)	-	-	-	-	-	-	-	-	-	-	2.01
IX	<b>Net Profit / (Loss) for the period from Continuing operations (VII-VIII)</b>	<b>1.47</b>	<b>33.08</b>	<b>6.84</b>	<b>9.68</b>	<b>17.90</b>	<b>12.84</b>	<b>(1.34)</b>	<b>67.19</b>	<b>11.88</b>	<b>83.68</b>	<b>93.39</b>	<b>94.77</b>
X	Profit / (Loss) from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XI	Tax Expense of discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XII	<b>Profit / (Loss) from discontinuing operations after tax</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XIII	<b>Profit/(Loss) for the Period (IX+XII)</b>	<b>1.47</b>	<b>33.08</b>	<b>6.84</b>	<b>9.68</b>	<b>17.90</b>	<b>12.84</b>	<b>(1.34)</b>	<b>67.19</b>	<b>11.88</b>	<b>83.68</b>	<b>93.39</b>	<b>94.77</b>
XIV	Other Comprehensive Incomes												
A)	(i) Items that will not be recycled to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(a) Others (gratuity and leave encashment excess provision reversal)	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
B)	(i) Items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	(ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-	-	-	-	-	-	-	-
	<b>Total Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XV	<b>Total Comprehensive Income for the period (XIII+XIV)</b>	<b>1.47</b>	<b>33.08</b>	<b>6.84</b>	<b>9.68</b>	<b>17.90</b>	<b>12.84</b>	<b>(1.34)</b>	<b>67.19</b>	<b>11.88</b>	<b>83.68</b>	<b>93.39</b>	<b>94.77</b>
	Profit Attributable to Shareholders of the Company	-	-	-	-	-	-	(0.74)	36.95	6.53	46.02	51.36	52.12
	Non-controlling interest	-	-	-	-	-	-	(0.60)	30.24	5.35	37.65	42.03	42.65
XVI	<b>Earnings Per Equity Share of face value of Rs.10/- each (for Continuing operations):</b>												
	1) Basic	0.01	0.28	0.06	0.08	0.15	0.11	(0.01)	0.31	0.05	0.38	0.43	0.43
	2) Diluted	0.01	0.28	0.06	0.08	0.15	0.11	(0.01)	0.31	0.05	0.38	0.43	0.43
XVII	<b>Earnings Per Equity Share of face value of Rs.10/- each (for Discontinuing operations):</b>												
	1) Basic	0.01	0.28	0.06	0.08	0.15	0.11	(0.01)	0.31	0.05	0.38	0.43	0.43
	2) Diluted	0.01	0.28	0.06	0.08	0.15	0.11	(0.01)	0.31	0.05	0.38	0.43	0.43
XVIII	<b>Earnings Per Equity Share of face value of Rs.10/- each (for Continued and Discontinuing operations):</b>												
	1) Basic	0.01	0.28	0.06	0.08	0.15	0.11	(0.01)	0.31	0.05	0.38	0.43	0.43
	2) Diluted	0.01	0.28	0.06	0.08	0.15	0.11	(0.01)	0.31	0.05	0.38	0.43	0.43
XIX	Paid-up equity share capital (Face Value of Rs. 10/- per share)	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00	1,200.00

**Notes:**

- In pursuance with Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III of the Companies Act, 2013, the above Financial Results have been prepared. The same is reviewed by the Statutory Auditors of Company and recommended by the Audit Committee and subsequently approved by the Board of Directors of Company at their meeting held on 14.02.2025.
- The Financial Statements have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS-34 'Interim Financial Reporting', presented under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and other accounting pronouncements generally accepted in India.
- The figures of the previous year/periods have been re-grouped/re-classified, wherever necessary, for the purpose of comparison with the current year/period figures.
- The Company is having operations only in One Segment i.e., Trading of Paper and other paper products. Hence Segment wise reporting as per Ind AS-108, is not applicable.
- Income tax/Deferred tax liabilities for the current period will be finalized at the end of the accounting year.
- The Consolidated Financial Results includes M/s VSR Paper and Packaging Limited (55% Subsidiary)
- The above Financial Results are also available on the company's website [www.bandaram.com](http://www.bandaram.com)

For and on Behalf of the Board of Directors  
Bandaram Pharma Packtech Limited  
(Formerly Known as Shiva Medicare Limited)

  
B. Deepak Reddy  
Managing Director  
DIN: 07074102

Place: Bangalore  
Date: 14-02-2025

**LIMITED REVIEW REPORT**

To,  
**The Board of Directors,**  
**BANDARAM PHARMA PACKTECH LIMITED**

We have reviewed the accompanying statement of Un-Audited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** for the quarter ended **31<sup>st</sup> December 2024** attaching herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and disclosure Requirements) Regulations, 2015, as amended.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standard) Rules, 2015 is the responsibility of the company management and has been approved by the Board of Directors of the Company. Our Responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information performed by the independent auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ( "Ind AS") specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **M M REDDY & CO.,**  
Chartered Accountants  
Firm Regn No 010371S

M Madhusudhana Reddy  
Partner

Membership No 213077

UDIN: 25213077BMIHOT3591

Place: Hyderabad  
Date: 14-02-2025



**Independent Auditor's Review Report on Interim Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To


Board of Directors of

**M/s. BANDARAM PHARMA PACKTECH LIMITED**

We have reviewed the quarterly Consolidated Unaudited Financial Results of **BANDARAM PHARMA PACKTECH LIMITED (formerly known as Shiva Medicare Limited)** ("The Company") and its subsidiaries (Collectively referred to as Group) for the quarter ended 31<sup>st</sup> December 2024 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

These quarterly consolidated financial results as well have been prepared on the basis of the consolidated interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these Consolidated financial results based on our audit of such Consolidated interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our review of the Statement in accordance with the standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity," issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Attention is drawn to the statement which states that the Consolidated figures for the Corresponding quarters ended September 30, 2024 as reported in the accompanying Statement have been approved by the Parent's Board of Directors, but have not been subjected to review.


We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

We did not review the interim financial information of Subsidiary company which are included in the consolidated quarterly unaudited financial results, whose consolidated interim financial information reflects, total revenues of VSR Paper and Packaging Limited is Rs. 955.22 Lakhs for the quarter ended 31<sup>st</sup> December 2024, total net profit of VSR Paper and Packaging Limited is Rs. 21.86 Lakhs and total comprehensive income/(loss) of VSR Paper and Packaging Limited is 21.86 Lakhs for the quarter ended 31<sup>st</sup> December, 2024. This interim financial information has been reviewed by other Auditors whose reports have been furnished to us by management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, based solely on the reports of the other auditors.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results:

- I. Include the quarterly financial results of the following entities: -
  - a) VSR Paper and Packaging Limited (Holding 55%)
- II. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard.

For M M REDDY & CO.,  
Chartered Accountants  
Firm Regn No.010371S

  
M. Madhusudhana Reddy  
Partner

Membership No.213077  
UDIN: 25213077BMIHOU4396



Place: Hyderabad  
Date: 14-02-2025